References
- Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802.
- Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov. 2012;11:25–36.
- Gatti L, Cossa G, Beretta GL, et al. Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem. 2011;18:4237–4249.
- Gatti L, Beretta GL, Cossa G, et al. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem. 2009;9:1102–1112.
- Chabot GG, Robert J, Lokiec F, et al. Irinotecan pharmacokinetics. Bull Cancer. 1998;Dec Spec No:11–20.
- Harel M, Hyatt JL, Brumshtein B, et al. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase. Chem Biol Interact. 2005;157-158:153–157.
- Morton CL, Wadkins RM, Danks MK, et al. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. 1999;59:1458–1463.
- Boyer J-C, Etienne-Grimaldi M-C, Thomas F, et al. Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan. Bull Cancer. 2014;101:533–553.
- Swami U, Goel S, Mani S. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets. 2013;14:777–797.
- Beretta GL, Zunino F. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem Pharmacol. 2007;74:1437–1444.
- Chazin Ede L, Reis Rda R, Junior WT, et al. An overview on the development of new potentially active camptothecin analogs against cancer. Mini Rev Med Chem. 2014;14:953–962.
- Yang L-X, Pan X, Wang H-J. Novel camptothecin derivatives. Part 1: oxyalkanoic acid esters of camptothecin and their in vitro and in vivo antitumor activity. Bioorg Med Chem Lett. 2002;12:1241–1244.
- Cao Z, Harris N, Kozielski A, et al. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem. 1998;41:31–37.
- De Groot FM, Busscher GF, Aben RW, et al. Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin. Bioorg Med Chem Lett. 2002;12:2371–2376.
- Lerchen HG, Baumgarten J, Von Dem Bruch K, et al. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem. 2001;44:4186–4195.
- Samorì C, Guerrini A, Varchi G, et al. The role of polyamine architecture on the pharmacological activity of open lactone camptothecin-polyamine conjugates. Bioconjug Chem. 2008;19:2270–2279.
- Beretta GL, Petrangolini G, De Cesare M, et al. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. Cancer Res. 2006;66:10976–10982.
- Kuo-Hsiung L, Keduo Q, Xiaoming Y, et al. Novel 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent. WO 2015048365 A1, 2015.
- Wang M-J, Liu Y-Q, Chang L-C, et al. Design, synthesis, mechanisms of action, and toxicity of novel 20(S)-sulfonylamidine derivatives of camptothecin as potent antitumor agents. J Med Chem. 2014;57:6008–6018.
- Bae I, Han H, Chang S. Highly efficient one-pot synthesis of N-sulfonylamidines by Cu-catalyzed three-component coupling of sulfonyl azide, alkyne, and amine. J Am Chem Soc. 2005;127:2038–2039.
- Zhao X-B, Wu D, Wang M-J, et al. Design and synthesis of novel spin-labeled camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem. 2014;22:6453–6458.
- Desai SD, Li TK, Rodriguez-Bauman A, et al. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001;61:5926–5932.
- Ulivi P, Zoli W, Fabbri F, et al. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. Neoplasia. 2005;7:152–161.
- Staker BL, Hjerrild K, Feese MD, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA. 2002;99:15387–15392.
- Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem. 2005;48:2336–2345.
- Gnoni A, Silvestris N, Licchetta A, et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol. 2015;95:46–61.